<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02459951</url>
  </required_header>
  <id_info>
    <org_study_id>4729FBD</org_study_id>
    <nct_id>NCT02459951</nct_id>
  </id_info>
  <brief_title>Improving Holding Function of the Hemiplegic Hand</brief_title>
  <official_title>Improving Holding Function of the Hemiplegic Hand With Chemodenervation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nathaniel Mayer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein Healthcare Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Relevant to patients with spastic hemiparesis in the hand and upper limb, this pilot project
      proposes to measure the effects of botulinum toxin injections through observation of
      performance on a functional task known as 'hand as a holder'. This task requires the person
      with hemiplegia to insert an object into the affected hand and hold it independently.

      The project aims to demonstrate reliability and validity of a digital video method that will
      be used to measure 'insertion time'. It also aims to establish initial statistical support
      for improved object insertion time into the hemiplegic clenched fist after Botox A
      injections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Holding is an everyday hand function, objects entering the hand radially, frontally, ulnarly
      or in-between the finger spaces. After a stroke, the hand of a person with hemiplegia
      typically lacks voluntary finger extension that opens the hand. Simultaneously, the hand is
      also subjected to involuntary contraction of finger flexor muscles that close the hand,
      resulting in clenched fist and thumb-in-palm deformities. Despite these typical hemiplegic
      configurations, persons with stroke may be able to insert an object into the hand by wiggling
      and pushing it into the hemiplegic hand with their uninvolved hand, though struggle is often
      present and failure is frequent. In the hemiplegic patient, a common driver of clenched fist
      and thumb-in-palm configurations is excessive involuntary neural activation of finger and
      thumb flexors, compounded by impaired or absent voluntary finger extension. Excessive finger
      and thumb flexor contractions have been variously ascribed to involuntary phenomena such as
      spasticity, spastic dystonia, co-contraction, associated reactions and others. For the
      investigators purpose here, these involuntary phenomena generate contractile tension in hand
      and thumb muscles that choke the hand's potential to function as a holder of objects as
      described above.

      The underlying rationale of this project is to examine whether hemiplegic 'hand as a holder'
      function can be improved by weakening involuntary muscle contractions that generate clenched
      fist and thumb in palm using the neuromuscular blocking properties of Botox A. The
      investigators hypothesize that 'hand as a holder' function will improve after
      chemodenervation of relevant finger, thumb and wrist muscles selected by clinical
      examination.

      Nine subjects will be enrolled. Baseline observations will be made on two occasions prior to
      Botox A injection and outcomes measured four weeks later. A digital video method will be used
      to measure 'insertion time' at all-time points. Given the importance of the relationship
      between &quot;statistically significant&quot; research results and &quot;clinically significant&quot;,
      person-oriented, functional improvement, the investigators also hypothesize that experienced
      clinicians will independently rate the performance of object insertion into the clenched fist
      as globally better after chemodenervation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">April 30, 2017</completion_date>
  <primary_completion_date type="Actual">January 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Ratios of Log-transformed Transit Time</measure>
    <time_frame>days post-injection evaluation (mean 26 days; range 21-30 days)</time_frame>
    <description>Time (log-transformed) required for contralateral hand to insert a plastic cylinder successfully into the hemiplegic clenched fist AND assessed at Pre-injection baseline 2 and a Post-injection session expressed as a geometric mean ratio of these sessions. (Success is defined by a hold of 5 secs or more). Geometric mean ratios are calculated for each of 5 cylinder sizes (A-E)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fraction of Successful Holds for Each Evaluation Session</measure>
    <time_frame>days between two baseline evaluations (mean 6; range 2-14) and days post-injection evaluation (mean 26; range 21-30)</time_frame>
    <description>fraction of successful holds for each evaluation session (Pre1, Pre2, and Post)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Successful Holds</measure>
    <time_frame>days between two baseline evaluations (mean 6; range 2-14) and days post-injection evaluation (mean 26; range 21-30)</time_frame>
    <description>ratio of successful holds post/pre1, post/pre2 or pre1/pre2</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Modified Ashworth Score (MAS)</measure>
    <time_frame>days between two baseline evaluations (mean 6; range 2-14) and days post-injection evaluation (mean 26; range 21-30)</time_frame>
    <description>A clinical ordinal measure of resistance to passive stretch of a limb on a scale of 0-4 with higher scores representing greater resistance</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>clenched fist</arm_group_label>
    <description>Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>clenched fist</intervention_name>
    <description>Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.</description>
    <arm_group_label>clenched fist</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients who are clinically appropriate for Botox A injection to treat upper limb
        spasticity due to stroke
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who are clinically appropriate for treatment of upper limb spasticity due to
             stroke with Botox A injections ;

          -  adults up to age 80, women must be post-menopausal or are medically unable to conceive
             (as determined from their medical records), men must be at least age 35

          -  documented anemic or hemorrhagic unilateral (right or left) hemiplegic stroke, with 1
             year or more prior to enrollment

          -  able to understand verbal and visual instructions and demonstrations regarding the
             protocol

          -  a resting wrist angle equal to or less than 0

          -  spasticity is present in finger flexors and thumb coupled with marked voluntary
             paresis of finger extension (no finger has more than half range of active extension at
             any joint). By squeezing the examiner's finger, participants will have demonstrated,
             at least, some detectable voluntary contraction of finger flexors; impaired sensation
             is acceptable but participants must be aware that they are holding something, as
             tested clinically;

          -  at least two finger flexors with an Ashworth score = 3;

          -  moderate motor severity as defined by an upper limb Fugl-Meyer motor scores between
             21-50

          -  normal joint capsule without contractures as determined by clinical exam; participant
             may have tightness/shortening of extrinsic finger flexors but composite extension of
             wrist and fingers comes to at least neutral (i.e. fingers and wrist can be brought to
             neutral position simultaneously).

        Exclusion Criteria:

          -  profound sensory loss/absent touch sensation

          -  known hypersensitivity/allergy to Botox A

          -  acute illness or unresolved medical/psychiatric conditions at time of assessment

          -  symptomatic lung disease and compromised respiratory status; muscle-weakening
             neurological disorders known to increase drug-related risk [e.g. amyotrophic lateral
             sclerosis (ALS), myasthenia gravis, Lambert-Eaton syndrome, or motor neuropathy]

          -  infection in the area where the study drug should be injected

          -  pregnancy or breast-feeding;

          -  participant had Botox injections less than 4 months previously

          -  clenched fist associated with tenodesis of an extended wrist i.e. resting position of
             wrist is &gt; 0 degrees
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathaniel Mayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein Healthcare Network</affiliation>
  </overall_official>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 14, 2015</study_first_submitted>
  <study_first_submitted_qc>May 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <results_first_submitted>May 12, 2017</results_first_submitted>
  <results_first_submitted_qc>April 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 1, 2019</results_first_posted>
  <last_update_submitted>July 5, 2019</last_update_submitted>
  <last_update_submitted_qc>July 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein Healthcare Network</investigator_affiliation>
    <investigator_full_name>Nathaniel Mayer</investigator_full_name>
    <investigator_title>Director, Motor Control Analysis Laboratory MossRehab</investigator_title>
  </responsible_party>
  <keyword>Muscle Spasticity</keyword>
  <keyword>Botox A</keyword>
  <keyword>Upper limb hemiplegia</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 29, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT02459951/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hemiplegic Clenched Fist</title>
          <description>Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.
clenched fist: Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unable to meet holding requirement</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hemiplegic Clenched Fist</title>
          <description>Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.
clenched fist: Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="52" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Months post stroke</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="24" upper_limit="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fugl-Meyer Assessment (upper limb motor score only)</title>
          <description>Scale range is 0 to 66 (upper extremity motor score only); higher score is better</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" lower_limit="10" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weinstein Enhanced Sensory Test (West)</title>
          <description>scale measures sensation using monofilament pressure; scale range is: 1.65 -6.65; lower score is better</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.42" lower_limit="2.83" upper_limit="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visual Neglect</title>
          <description>The presence of visual neglect as determined by clinical examination</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>dominant hand is affected</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>days between the two baseline evaluations</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6" lower_limit="2" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>days post injection evaluation</title>
          <description>number of days after participants were injected with OnabotulinumtoxinA and then evaluated</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" lower_limit="21" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Ratios of Log-transformed Transit Time</title>
        <description>Time (log-transformed) required for contralateral hand to insert a plastic cylinder successfully into the hemiplegic clenched fist AND assessed at Pre-injection baseline 2 and a Post-injection session expressed as a geometric mean ratio of these sessions. (Success is defined by a hold of 5 secs or more). Geometric mean ratios are calculated for each of 5 cylinder sizes (A-E)</description>
        <time_frame>days post-injection evaluation (mean 26 days; range 21-30 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hemiplegic Clenched Fist</title>
            <description>Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.
clenched fist: Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Ratios of Log-transformed Transit Time</title>
          <description>Time (log-transformed) required for contralateral hand to insert a plastic cylinder successfully into the hemiplegic clenched fist AND assessed at Pre-injection baseline 2 and a Post-injection session expressed as a geometric mean ratio of these sessions. (Success is defined by a hold of 5 secs or more). Geometric mean ratios are calculated for each of 5 cylinder sizes (A-E)</description>
          <units>dimensionless ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>cylinder A (.5 &quot; diameter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="0.99" upper_limit="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cylinder B (1&quot; diameter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="0.89" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cylinder C (1.5&quot; diameter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" lower_limit="0.65" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cylinder D (2&quot; diameter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.57" upper_limit="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cylinder E (2.5&quot; diameter)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.51" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.059</p_value>
            <p_value_desc>refer to cylinder A (.5&quot; diameter)</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.465</p_value>
            <method>Regression, Logistic</method>
            <method_desc>refer to cylinder B(1&quot; diameter)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.022</p_value>
            <p_value_desc>refer to cylinder C (1.5&quot; diameter)</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.004</p_value>
            <p_value_desc>refer to cylinder D (2&quot; diameter)</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.002</p_value>
            <p_value_desc>refer to cylinder E (2.5&quot; diameter)</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fraction of Successful Holds for Each Evaluation Session</title>
        <description>fraction of successful holds for each evaluation session (Pre1, Pre2, and Post)</description>
        <time_frame>days between two baseline evaluations (mean 6; range 2-14) and days post-injection evaluation (mean 26; range 21-30)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hemiplegic Clenched Fist</title>
            <description>Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.
clenched fist: Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Successful Holds for Each Evaluation Session</title>
          <description>fraction of successful holds for each evaluation session (Pre1, Pre2, and Post)</description>
          <units>fraction of successful holds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>post injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".67" lower_limit=".48" upper_limit=".95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre 1 baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".51" lower_limit=".37" upper_limit=".72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre2 baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".53" lower_limit=".37" upper_limit=".77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Successful Holds</title>
        <description>ratio of successful holds post/pre1, post/pre2 or pre1/pre2</description>
        <time_frame>days between two baseline evaluations (mean 6; range 2-14) and days post-injection evaluation (mean 26; range 21-30)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clenched Fist</title>
            <description>Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.
clenched fist: Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Successful Holds</title>
          <description>ratio of successful holds post/pre1, post/pre2 or pre1/pre2</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>post vs. pre1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" lower_limit="1.05" upper_limit="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>post vs pre2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" lower_limit="1.02" upper_limit="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pre1 vs pre2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".96" lower_limit=".71" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Modified Ashworth Score (MAS)</title>
        <description>A clinical ordinal measure of resistance to passive stretch of a limb on a scale of 0-4 with higher scores representing greater resistance</description>
        <time_frame>days between two baseline evaluations (mean 6; range 2-14) and days post-injection evaluation (mean 26; range 21-30)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Clenched Fist</title>
            <description>Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.
clenched fist: Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Ashworth Score (MAS)</title>
          <description>A clinical ordinal measure of resistance to passive stretch of a limb on a scale of 0-4 with higher scores representing greater resistance</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre2 vs Pre1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post vs. Pre1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-2" upper_limit="-1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post vs. Pre2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" lower_limit="-2" upper_limit="-1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>until 5 weeks post injection</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hemiplegic Clenched Fist</title>
          <description>Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.
clenched fist: Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nathaniel Mayer MD</name_or_title>
      <organization>Albert Einstein Healthcare Network</organization>
      <phone>215 663 6681</phone>
      <email>nmayer@einstein.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

